Category: PRESS RELEASES

SmartEdge Partner Program Winners Are Tech Data, SHI, Presidio, Atlantik, Arki, Data Equipment, Acromax, Rahi System India and Enthu Technology Sdn. Bhd.

IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) — Lantronix Inc. (NASDAQ: LTRX), a global provider of secure turnkey solutions for the Internet of Things (IoT) and Remote Environment Management (REM) offering Software as a Service (SaaS), connectivity services, engineering services and intelligent hardware, today announced the winners of its SmartEdge™ Partner Program Awards. The awards were given at Lantronix’s 2021 SmartEdge Partner Summit held virtually on June 23, 2021.

Lantronix’s SmartEdge Partner Program Awards were given to winners in three categories: Distribution Partner, StrategicEdge Partner and Edge Partner covering three regions: North America, Europe/Middle East/Africa and Asia Pacific.

The winners are:
North America
North America Distributor Partner of the Year: Tech Data
North America StrategicEdge Partner of the Year: SHI
North America Edge Partner of the Year: Presidio

Europe/Middle East/Africa (EMEA)
EMEA Distributor Partner of the Year: Atlantik Elektronik
EMEA StrategicEdge Partner of the Year: Arki Technology
EMEA Edge Partner of the Year: Data Equipment

Asia Pacific (APAC)
APAC Distributor Partner of the Year: Acromax
APAC StrategicEdge Partner of the Year: Rahi Systems, India
APAC Edge Partner of the Year: Enthu Technology Sdn. Bhd.

“We are pleased to honor the SmartEdge Partner Program winners, all of which have exceeded our program requirements and expectations in driving sales and building long-term relationships with our mutual customers,” said Roger Holliday, VP of WW Sales at Lantronix.

SmartEdge Partner Program One-Year Anniversary

Lantronix celebrated the one-year anniversary of its new SmartEdge Partner Program in April 2021. “The Lantronix SmartEdge Partner Program has attracted the industry’s top channel partners,” said Jonathan Shipman, VP of Strategy at Lantronix. “With our SmartEdge Program, our channel partners offer Lantronix’s integrated offering of software, hardware and service solutions, providing their customers with everything they need to build robust, secure connectivity-based solutions.”

Lantronix Named to CRN Partner Program Guide

Lantronix’s SmartEdge Partner Program has been named to the industry’s leading partner program guide, the CRN Partner Program Guide. Published by CRN^®, a brand of The Channel Company, this annual guide provides a conclusive list of the most distinguished partner programs from leading technology companies that provide products and services through the IT Channel. The 2021 Partner Program Guide is online at www.CRN.com/PPG.

About the SmartEdge Partner Program

Lantronix’s SmartEdge™ Partner Program was designed to help Value-Added Resellers (VARs) and Systems Integrators (SIs) drive revenues by differentiating their offerings with Lantronix’s innovative Industrial Internet of Things (IoT), Remote Environment Management (REM), Out-of-Band Management (OOBM) and Mobility/Connectivity solutions.
For more information on the Lantronix SmartEdge Partner Program, visit www.lantronix.com/partners.

About Lantronix

Lantronix Inc. is a global provider of secure turnkey solutions for the Internet of Things (IoT) and Remote Environment Management (REM), offering Software as a Service (SaaS), connectivity services, engineering services and intelligent hardware. Lantronix enables its customers to provide reliable and secure solutions while accelerating their time to market. Lantronix’s products and services dramatically simplify operations through the creation, development, deployment and management of customer projects at scale while providing quality, reliability and security.

With three decades of proven experience in creating robust IoT technologies and OOBM solutions, Lantronix is an innovator in enabling its customers to build new business models, leverage greater efficiencies and realize the possibilities of the Internet of Things. Lantronix’s solutions are deployed inside millions of machines at data centers, offices and remote sites serving a wide range of industries, including energy, agriculture, medical, security, manufacturing, distribution, transportation, retail, financial, environmental and government.

Lantronix is headquartered in Irvine, Calif. For more information, visit www.lantronix.com. Learn more at the Lantronix blog, www.lantronix.com/blog, featuring industry discussion and updates. To follow Lantronix on Twitter, please visit www.twitter.com/Lantronix. View our video library on YouTube at www.youtube.com/user/LantronixInc or connect with us on LinkedIn at www.linkedin.com/company/lantronix.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995: Any statements set forth in this news release that are not entirely historical and factual in nature, including without limitation statements related to our solutions, technologies and products are forward-looking statements. These forward-looking statements are based on our current expectations and are subject to substantial risks and uncertainties that could cause our actual results, future business, financial condition, or performance to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this news release. The potential risks and uncertainties include, but are not limited to, such factors as the effects of negative or worsening regional and worldwide economic conditions or market instability on our business, including effects on purchasing decisions by our customers; the impact of the COVID-19 outbreak on our employees, supply and distribution chains, and the global economy; cybersecurity risks; changes in applicable U.S. and foreign government laws, regulations, and tariffs; our ability to successfully implement our acquisitions strategy or integrate acquired companies; difficulties and costs of protecting patents and other proprietary rights; the level of our indebtedness, our ability to service our indebtedness and the restrictions in our debt agreements; and any additional factors included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2020, filed with the Securities and Exchange Commission (the “SEC”) on September 11, 2020, including in the section entitled “Risk Factors” in Item 1A of Part I of such report, as well as in our other public filings with the SEC. Additional risk factors may be identified from time to time in our future filings. The forward-looking statements included in this release speak only as of the date hereof, and we do not undertake any obligation to update these forward-looking statements to reflect subsequent events or circumstances.

© 2021 Lantronix, Inc. All rights reserved. Lantronix is a registered trademark, and EMG and ConsoleFlow are trademarks of Lantronix Inc. Other trademarks and trade names are those of their respective owners.

© 2021. CRN is a registered trademark of The Channel Company, LLC. All rights reserved.

Lantronix Media Contact:
Gail Kathryn Miller
Corporate Marketing &
Communications Manager
media@lantronix.com
949-453-7158

Lantronix Analyst and Investor Contact:
Jeremy Whitaker
Chief Financial Officer
investors@lantronix.com
949-450-7241

Lantronix Sales:
sales@lantronix.com
Americas +1 (800) 422-7055 (US and Canada) or +1 949-453-3990
Europe, Middle East and Africa +31 (0)76 52 36 744
Asia Pacific + 852 3428-2338
China + 86 21-6237-8868
Japan +81 (0) 50-1354-6201
India +91 994-551-2488

ข้อตกลงใหม่ขยายขอบเขตการเข้าถึงทั่วโลกของ Conformis และนำระบบการผ่าตัดเปลี่ยนข้อเข่าเทียมเฉพาะผู้ป่วยไปสู่ตลาดที่ใหญ่ที่สุดในภูมิภาคเอเชียแปซิฟิก

BILLERICA, Mass., June 24, 2021 (GLOBE NEWSWIRE) — Conformis, Inc. (NASDAQ:CFMS) วันนี้ได้ประกาศการดำเนินการตามข้อตกลงเพื่อเข้าสู่ตลาดเอเชียแปซิฟิกผ่านความสัมพันธ์การจัดจำหน่ายแบบเอกสิทธิ์เฉพาะบุคคลกับ XR Medical Group (Hong Kong) Limited (XR Medical)

ภายใต้ข้อตกลงการจัดจำหน่าย XR Medical จะได้รับสิทธิพิเศษในการขาย ทำการตลาด และการจัดจำหน่ายระบบการผ่าตัดเปลี่ยนข้อเข่าเทียมแบบทั้งหมด iTotal^® CR & PS เฉพาะผู้ป่วยของ Conformis, อุปกรณ์สำหรับกระดูกสะบ้า iTotal^® CR & PS และระบบการผ่าตัดข้อเข่าเทียมชนิดบางส่วน iUni^® และ iDuo^® ผลิตภัณฑ์อื่นๆ เช่น ระบบสำหรับหัวเข่า Identity Imprint™ ที่ได้รับอนุมัติเมื่อไม่นานมานี้ของ Conformis และกลุ่มผลิตภัณฑ์สำหรับสะโพกของบริษัท ซึ่งอาจถูกเพิ่มเข้ามาในอนาคต

ทีมงานฝ่ายขายของ XR Medical จะมอบการขายและการสนับสนุนเฉพาะสำหรับสิ่งอำนวยความสะดวกระดับสูงใน Boao Lecheng International Medical Tourism Pilot Zone (เขตการค้าเสรีนำร่อง) ของไห่หนานในนามของ Conformis ภูมิภาคนี้เป็นศูนย์กลางการท่องเที่ยวทางการแพทย์ที่สำคัญสำหรับหลายสิบประเทศ

“ข้อตกลงการจัดจำหน่ายนี้เป็นอีกตัวอย่างหนึ่งของความคืบหน้าในขณะที่เราดำเนินกลยุทธ์การเติบโตโดยรวมของเรา เรามั่นใจว่ากลุ่มผลิตภัณฑ์ที่โดดเด่นของเราจะช่วยเร่งความเติบโตระดับสากลของ Conformis ได้ และเรายินดีที่จะเป็นพันธมิตรกับ XR Medical ซึ่งมีประวัติความสำเร็จที่น่าประทับใจในประเทศจีน” Mark Augusti ประธานและ CEO ของ Conformis กล่าว “สิ่งที่น่าสนใจเป็นพิเศษเกี่ยวกับ XR Medical คือประสิทธิภาพที่แข็งแกร่งในเขตการค้าเสรีนำร่อง ด้วยการเข้าถึงผู้ป่วยที่เข้ามาในภูมิภาคเพื่อรับการรักษา จะทำให้เกิดโอกาสที่จะแนะนำกลุ่มเป้าหมายที่กว้างขวางเกี่ยวกับประโยชน์ทางคลินิกของเทคโนโลยี Conformis เราเชื่อว่าการเริ่มต้นในเขตการค้าเสรีนำร่องทำให้เราอยู่ในตำแหน่งที่ดี และเราคาดว่าความสัมพันธ์นี้จะเป็นแบบอย่างสำหรับโอกาสในการขยายตัวในอนาคตในจีนแผ่นดินใหญ่”

เขตการค้าเสรีนำร่องตั้งอยู่บนไหหลำ ซึ่งเป็นเกาะขนาดใหญ่นอกชายฝั่งทางใต้ของจีน ซึ่งจัดตั้งขึ้นในปี 2019 เพื่อดึงดูดพลเมืองชาวจีนที่มีฐานะมั่งคั่งซึ่งอาจจะไปต่างประเทศเพื่อรับการดูแลทางการการแพทย์ เขตภูมิภาคนี้ของจีนได้พัฒนาสถานรักษาพยาบาลระดับสูงในจุดหมายปลายทางยอดนิยม ปัจจุบัน นักท่องเที่ยวทางการแพทย์จากหลายสิบประเทศ รวมทั้งในเอเชียตะวันออกเฉียงใต้ ได้รับอนุญาตให้เข้าพักที่ไหหลำได้ 30 วันโดยไม่ต้องขอวีซ่า

ตลาดโลกสำหรับการฟื้นฟูข้อเข่าคาดว่าจะมีมูลค่ามากกว่า 9 พันล้านดอลลาร์ จากทั้งหมดนี้ คาดว่าตลาดการฟื้นฟูข้อเข่าในภูมิภาคเอเชียแปซิฟิกในปัจจุบันจะมีมูลค่าเกิน 1.7 พันล้านดอลลาร์ Fortune Business Insights คาดการณ์อัตราการเติบโตสูงสำหรับการผ่าตัดเปลี่ยนข้อเข่าเทียมในภูมิภาคนี้ อันเนื่องมาจากจำนวนของอาการข้อเข่าเสื่อมที่เพิ่มขึ้น การท่องเที่ยวเชิงการแพทย์ที่เฟื่องฟู รายได้ที่เพิ่มขึ้น และโครงสร้างพื้นฐานด้านการดูแลสุขภาพที่ดีขึ้น

เกี่ยวกับ Conformis, Inc.

Conformis เป็นบริษัทเทคโนโลยีทางการแพทย์ที่ใช้แพลตฟอร์มเทคโนโลยี iFit^® Image-to-Implant® ที่เป็นกรรมสิทธิ์ เพื่อพัฒนา ผลิต และจำหน่ายการปลูกถ่ายและอุปกรณ์สำหรับข้อเข่าที่มีขนาดและรูปทรงแตกต่างกัน ซึ่งเราหมายความว่าเป็นส่วนบุคคล เฉพาะบุคคล หรือบางครั้งก็หมายความว่าปรับแต่งเอง เพื่อให้เหมาะสมและสอดคล้องกับกายวิภาคของผู้ป่วยแต่ละราย Conformis นำเสนอผลิตภัณฑ์ปลูกถ่ายข้อเข่าและสะโพกเฉพาะบุคคลและผลิตภัณฑ์ปลูกถ่ายแบบมาตรฐานหลากหลายที่ปลอดเชื้อ พร้อมด้วยเครื่องมือแบบใช้ครั้งเดียวที่ส่งไปยังโรงพยาบาลและศูนย์ศัลยกรรมผู้ป่วยนอก ในการศึกษาทางคลินิก ระบบการผ่าตัดเปลี่ยนข้อเข่าเทียม Conformis iTotal^® CR แสดงให้เห็นผลลัพธ์ทางคลินิกที่เหนือกว่า รวมถึงการทำงานที่ดีขึ้นและความพึงพอใจของผู้ป่วยมากกว่า เมื่อเทียบกับการปลูกถ่ายแบบดั้งเดิมที่มีจำหน่ายตามท้องตลาด Conformis เป็นเจ้าของหรือผู้ที่ได้รับสิทธิบัตรหรือการใช้งานที่อยู่ระหว่างการจดสิทธิบัตรที่รอดำเนินการ ซึ่งครอบคลุมการปลูกถ่ายส่วนบุคคลและเครื่องมือเฉพาะของผู้ป่วยสำหรับข้อต่อที่สำคัญทั้งหมด

สำหรับข้อมูลเพิ่มเติม โปรดไปที่ www.conformis.com หากต้องการรับการแจ้งเตือนทางอีเมลในอนาคต โปรดลงทะเบียนที่ http://ir.conformis.com

หมายเหตุข้อควรระวังเกี่ยวกับข้อความเชิงคาดการณ์เหตุการณ์ในอนาคต

ข้อความในข่าวประชาสัมพันธ์ฉบับนี้เกี่ยวกับความคาดหวัง แผนงาน และแนวโน้มในอนาคตของเรา ตลอดจนข้อความอื่นๆ ที่มีคำว่า “คาดการณ์”, “เชื่อ”, “ดำเนินการต่อ”, “สามารถ”, “ประมาณ”, “คาดว่า”, “ตั้งใจ”, “อาจจะ”, “อาจ”, “วางแผน”, “มีแนวโน้ม”, “คาดเดา”, “มีโครงการ”, “ควรจะ”, “เป้าหมาย”, “จะ” หรือ “น่าจะ” และสำนวนที่คล้ายคลึงกันถือเป็นข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตตามความหมายของบทบัญญัติการจำกัดความรับผิดชอบของกฎหมายปฏิรูปการฟ้องร้องคดีหลักทรัพย์ส่วนบุคคลปี 1995 คุณไม่ควรเชื่อถือข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตมากเกินไป ผลลัพธ์ที่แท้จริงอาจแตกต่างอย่างมากจากการคาดการณ์ที่เปิดเผยในข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตที่เราทำอันเป็นผลมาจากความเสี่ยงและความไม่แน่นอนต่างๆ รวมถึงความเสี่ยงและความไม่แน่นอนที่อธิบายไว้ในส่วน “ปัจจัยเสี่ยง” ของเอกสารที่ยื่นต่อสาธารณะของเรากับสำนักงานคณะกรรมการกำกับหลักทรัพย์และตลาดหลักทรัพย์ นอกจากนี้ ข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตที่รวมอยู่ในข่าวประชาสัมพันธ์ฉบับนี้แสดงถึงมุมมองของเรา ณ วันที่ในที่นี้ เราคาดหวังว่าเหตุการณ์และการพัฒนาที่ตามมาอาจส่งผลให้มุมมองของเราเปลี่ยนแปลงได้ อย่างไรก็ตาม ในขณะที่เราอาจเลือกที่จะปรับปรุงข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตเหล่านี้ในบางจุดในอนาคต เราขอปฏิเสธภาระผูกพันใดๆ ที่จะต้องดำเนินการดังกล่าว ไม่ควรยึดถือข้อความเชิงคาดการณ์เหตุการณ์ในอนาคตเหล่านี้ว่าเป็นการแสดงความเห็นของเรา ณ วันที่ใดๆ ต่อจากวันที่ในที่นี้

ที่มา: Conformis, Inc.

ติดต่อด้านสื่อ:
ข้อมูลติดต่อสำหรับนักลงทุนสัมพันธ์
ir@conformis.com
(781) 374-5598

TeraRecon Announces Dan McSweeney President

DURHAM, N.C., June 24, 2021 (GLOBE NEWSWIRE) — Advanced visualization and AI leader TeraRecon, a SymphonyAI company, today announced the appointment of Dan McSweeney as president. He will be responsible for continuing and expanding TeraRecon’s leadership in healthcare advanced visualization and enterprise AI.

“TeraRecon is known for its strong reputation as the leader in advanced visualization and AI innovation in healthcare,” said McSweeney. “We are reinvesting the benefits of that leadership into delivering further value for organizations by maintaining excellence in advanced visualization and clinical workflow applications, as well as implementing next-gen, AI-based technologies for superior outcomes for patients and communities.”

TeraRecon leads the medical advanced visualization and AI market with its flagship Intuition product, delivering real-time imaging decision support for radiology, cardiology, vascular surgery, and more. Intuition is the 3D imaging market share leader in the US and the 2021 KLAS category leader for advanced visualization.

“TeraRecon has a long history of innovation and delivering customer value. Dan will help TeraRecon build on this history by accelerating AI-driven visualization and clinical solutions,” said Romesh Wadhwani, chairman and founder of TeraRecon’s parent company, SymphonyAI. “Dan’s track record of creating and expanding value through continuous solution improvement and deployment will serve the TeraRecon team well. He understands the importance of driving down barriers to adoption by making AI solutions valuable, practical, and ubiquitous.”

McSweeney brings to TeraRecon more than 20 years of strategic healthcare experience, with a strong track record of customer-centric growth. He spent 18 years with GE Capital and GE Healthcare in multiple executive roles. Most recently, he was at Wolters Kluwer Health, where he led the company’s $500 million business in the Americas.

About TeraRecon: TeraRecon, a SymphonyAI business, is a leader in advanced imaging and visualization AI and clinical AI solutions with a mission to continuously redefine patient and healthcare. The flagship Intuition product is the 2021 KLAS category leader for advanced visualization and holds the number one market share in 3D imaging in the US. TeraRecon is continuing to innovate ahead of customer demand with sophisticated healthcare-focused AI platform solutions unlike any in the world today.

About SymphonyAI

SymphonyAI is building the leading enterprise AI company for digital transformation across the most important and resilient growth verticals, including life sciences, healthcare, retail, consumer packaged goods, financial services, manufacturing, and media. In each of these verticals, SAI businesses have many of the leading enterprises as clients. SAI is backed by a $1 billion commitment from Dr. Romesh Wadhwani, a successful entrepreneur and philanthropist. Since its founding in 2017, SymphonyAI has grown rapidly to over 2,200 talented leaders, data scientists, and other professionals.

For more information, visit www.terarecon.com or info@terarecon.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f634d796-76e4-4209-871b-ee8a912b4f69

XIAN, China, June 23, 2021 (GLOBE NEWSWIRE) — Bon Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the pricing of its firm commitment initial public offering of 2,200,000 ordinary shares, par value US$0.0001 per share (the “Shares”) at a public offering price of $5.00 per Share (the “Offering”), for total gross proceeds of $11.0 million, before deducting underwriting discounts, commissions and other related expenses. In addition, BON has granted the underwriters a 45-day option to purchase up to an additional 330,000 Shares at the public offering price, less underwriting discount and commissions. The Shares are expected to begin trading on the Nasdaq Capital Market under the ticker symbol “BON” on June 24, 2021. The Offering is expected to close on or about June 28, 2021, subject to the satisfaction of customary closing conditions.

The Company intends to use the proceeds for working capital, to expand their sales and distribution network, research and development, and to expand production capacity.

U.S. Tiger Securities, Inc. and Newbridge Securities Corporation are acting as co-lead book running managers, and R.F. Lafferty & Co. Inc. is acting as the joint lead book running manager.

The Company’s securities described above are being offered pursuant to an effective registration statement on Form F-1 (SEC File No. 333-251182), that was previously filed with the Securities and Exchange Commission (“SEC”) on May 14, 2021, subsequently amended and declared effective on June 23, 2021, a copy of which has been filed with the SEC and is available on the SEC’s website at www.sec.gov. The Offering is being made only by means of such prospectus.

This press release contains information about the pending Offering of securities, and there can be no assurance that the Offering will be completed.

This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor may there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Bon Natural Life Limited

The Company focuses on the manufacturing of personal care ingredients, such as plant extracted fragrance compounds for perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements by their customers. For additional information, please visit the Company’s website at www.bnlus.com.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the natural, health and personal care market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward–looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

In the United States:	In China:
Maggie Zhang | Impact IR	Sophie Zhang| Impact IR
Phone: (646) 893-8916
Email: maggie.zhang@irimpact.com	Email: sophie.zhang@irimpact.com

New additions reflect the diverse, global perspective of the business school community

RESTON, Va., June 23, 2021 (GLOBE NEWSWIRE) — The Graduate Management Admission Council™ (GMAC™), a global association of leading graduate business schools, today announced the addition of four new members to its board of directors. Katy Montgomery, Associate Dean, Degree Programmes, INSEAD; François Ortalo-Magné, Dean, London Business School; and Giuseppe Soda, Dean, SDA Bocconi School of Management, Bocconi University, will begin their terms on July 1. In addition, Yuan Ding, Vice President and Dean of China Europe International Business School (CEIBS), was appointed as a board director in January this year to fill the seat vacated by Enase Okonedo of the Pan-Atlantic University.

“GMAC’s new board of directors represent leading business schools with campuses located in 10 countries across Europe, Asia, North America, Africa, and the Middle East,” said Sangeet Chowfla, president and CEO of GMAC. “As student mobility returns and regains in the post-pandemic world, I look forward to working alongside this diverse group of leaders ― and the rest of the GMAC board ― to continue to advance GMAC’s vision to ensure that all talented individuals can benefit from the best business education for them.”

New GMAC Board Members

Yuan Ding, Vice President and Dean, Cathay Capital Chair in Accounting, CEIBS

Yuan Ding is Vice President and Dean and the Cathay Capital Chair Professor in Accounting at CEIBS, where he has been honored three times with the CEIBS Teaching Excellence Award. Prior to joining CEIBS, he was a tenured faculty member of the HEC School of Management, Paris, France. He is a member of the European Accounting Association, French Accounting Association and American Accounting Association. He holds a PhD in Accounting from the Institute of Enterprises Administration at the University Montesquieu Bordeaux IV, France, as well as a Master’s in Enterprises Administration from the University of Poitiers, France. Ding is the author of multiple books on financial reporting and his research appears in leading academic journals.

Katy Montgomery, Associate Dean, Degree Programmes, INSEAD

As the INSEAD Associate Dean of Degree Programmes, Montgomery is responsible for the commercial leadership of the INSEAD Degree Programme portfolio across four campuses: Fontainebleau, Singapore, Abu Dhabi, and San Francisco. Her functional responsibilities include strategy, marketing, sales, admissions, financial aid and scholarships, programme operations, student life, psychological services, and career services. Prior to joining INSEAD, she served as Associate Dean of Student Development at Johns Hopkins Carey Business School. Montgomery holds a degree in Political Science from Loyola University New Orleans and a Juris Doctor degree from Georgetown University Law Center.

François Ortalo-Magné, Dean, London Business School

François Ortalo-Magné is the ninth Dean of London Business School (LBS), a position he has held since August 2017. He is leading a strategy focused on (1) academic research and its impact, (2) learning innovations and alumni engagement and (3) inclusion, striving for gender parity and greater socio-economic and ethnic diversity. Since taking up the role, Ortalo-Magné has led the relaunch of the LBS brand, the growth of degree programmes and a significant increase in philanthropic support for scholarships. His research on the economics of land and housing markets has been published in leading academic journals. He has built on his research and leadership experiences to advise a broad range of private, governmental and multi-lateral organisations and share his insights in leading media outlets and at conferences around the world. Prior to his appointment, Ortalo-Magné was the Albert O. Nicholas Dean and Robert E. Wangard Professor of Real Estate at the Wisconsin School of Business. His first academic appointment was at the London School of Economics.

Giuseppe Soda, Dean, SDA Bocconi School of Management, Bocconi University

Giuseppe “Beppe” Soda is the Dean of SDA Bocconi School of Management and Full Professor of Organization Theory and Network Analysis at Bocconi University. Before becoming Dean in 2016, his roles have included serving as the Associate Dean for Research (2007-2013), Director of the Department of Management and Technology (2013-2016) and Head of Organization and HRM Department (2001-2006). He is also serving EFMD as member of the EQUIS Accreditation Board. Soda’s research investigates the performance consequences of the interplay between organizational architectures and organizational networks and his work has been published in top academic management journals.

Besides the aforementioned newly elected board members, Martin Boehm, Professor of Marketing and former Dean of IE Business School and soon the new Rector of EBS Universität für Wirtschaft und Recht, and Themin Suwardy, Dean of Postgraduate Professional Programmes, Singapore Management University, were re-elected for a second term.

GMAC also recognizes its outgoing board members, Leila Guerra, Vice Dean (Education) of Imperial College Business School, and Peter Tufano, Peter Moores Dean and Professor of Finance of Saïd Business School, University of Oxford. GMAC thanks them for their service in the past nearly four years to our organization and contributions to the graduate management education community.

About GMAC™

The Graduate Management Admission Council™ (GMAC™) is a mission-driven association of leading graduate business schools worldwide. Founded in 1953, GMAC creates solutions and experiences that enable business schools and candidates to better discover, evaluate, and connect with each other.

GMAC provides world-class research, industry conferences, recruiting tools, and assessments for the graduate management education industry, as well as tools, resources, events, and services that help guide candidates through their higher education journey. Owned and administered by GMAC, the Graduate Management Admission Test™ (GMAT™) exam is the most widely used graduate business school assessment.

GMAC also owns and administers the NMAT by GMAC™ (NMAT™) exam and the Executive Assessment (EA). More than 7 million candidates on their business master’s or MBA journey visited GMAC’s mba.com last year to explore business school options, prepare and register for exams, and get advice on the admissions process. BusinessBecause and The MBA Tour are subsidiaries of GMAC, a global organization with offices in China, India, the United Kingdom, and the United States.

To learn more about our work, please visit www.gmac.com.

Media Contact:

Teresa Hsu
Sr. Manager, Media Relations
202-390-4180 (mobile)
thsu@gmac.com

Industry Veterans Join Team to Support the Development of Novel Cyclic Aspiration System for Ischemic Stroke

MIAMI, June 23, 2021 (GLOBE NEWSWIRE) — RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced the closing of a $15 million Series A financing. The financing was led by Santé Ventures who was joined by Epidarex Capital, Hatteras Venture Partners, Broadview Ventures, and Syntheon. RapidPulse plans to use the proceeds to advance its RapidPulse™ Cyclic Aspiration System through expanded clinical evaluation and build out its platform of proprietary catheters.

The RapidPulse™ system was developed by Syntheon, a medical device incubator focused on developing next generation medical devices. Their various products, commercialized by the largest and most trusted medical device companies in the world, have treated over 50 million patients globally in applications ranging from laparoscopic surgery, cardiovascular, and flexible endoscopy. Syntheon has over 200 issued patents since its inception over 20 years ago.

“We are pleased to have partnered with an outstanding investor syndicate to move our RapidPulse™ technology forward in the clinic,” said Sean McBrayer, CEO of Syntheon who will also serve as initial CEO of RapidPulse. “Stroke is the second leading cause of death and the third leading cause of disability worldwide, and minutes matter in improving these outcomes. This investment will help us expand our clinical results and move towards regulatory approval in the United States.”

Joining the team are industry veterans Heather Harries and Cynthia Yang. Heather most recently served as General Manager for Terumo’s aortic business and will lead product development and operations for RapidPulse. Cynthia will lead clinical development for the company, after most recently working in the neurovascular division of Medtronic.

Dennis McWilliams, partner at Santé Ventures, added, “Heather and Cynthia bring exceptional domain expertise to the team at RapidPulse, and will complement the significant engineering development experience at Syntheon. RapidPulse is a disruptive platform opportunity in neurovascular, and has the potential to significantly improve patient outcomes for ischemic stroke patients.”

ABOUT RAPIDPULSE

RapidPulse, Inc. is a privately held medical device company that develops minimally invasive vascular products for ischemic stroke. The company is advancing the development of the RapidPulse™ Cyclic Aspiration System, which includes a novel aspiration pump to allow rapid and consistent removal of blood clots from the brain. RapidPulse is a spinout of Syntheon LLC., a medical device incubator dedicated to developing innovative products in the medical device industry. Visit www.rapidpulsemed.com for more information.

ABOUT SANTÉ VENTURES

Santé Ventures is a life sciences investment firm that invests in early-stage companies in medical device, biotechnology, and digitally enabled health services. We partner with entrepreneurs to build impactful companies, including Claret Medical (now part of Boston Scientific), TVA Medical (Becton Dickinson), Millipede Medical (Boston Scientific), and Molecular Templates (NASDAQ: MTEM). Founded in 2006, Santé has just under $1 billion in assets under management, and has offices in Austin, TX and Boston, MA. For more information, please visit sante.com.

ABOUT EPIDAREX CAPITAL

Epidarex Capital is a transatlantic venture capital firm that builds exceptional life science companies in emerging hubs in the US and UK. Epidarex’s experienced team of early-stage investors partner with entrepreneurs and leading research institutions to transform world-class science into highly innovative products addressing major unmet needs in global healthcare. For more information, please visit www.epidarex.com

ABOUT HATTERAS VENTURE PARTNERS

Founded in 2000 and based in Durham, NC, Hatteras Venture Partners is a venture capital firm with a focus on seed and early stage healthcare investing. Through six funds and over $600 million under management, the firm has invested in breakthrough science and entrepreneurial grit in the areas of biopharmaceuticals, medical devices, diagnostics, healthcare IT, and related opportunities in human medicine. To learn more, please visit www.hatterasvp.com.

ABOUT BROADVIEW VENTURES

Founded in 2008, Broadview Ventures is a mission-driven investment organization. Broadview’s primary goal is to improve human health in the areas of cardiovascular disease and stroke through investments in early stage companies developing innovative therapeutics, devices, and diagnostics. For more information about Broadview Ventures, visit broadviewventures.org.

MEDIA CONTACT:

Sean McBrayer, info@rapidpulsemed.com, 305-266-3388

PHOENIX, June 23, 2021 (GLOBE NEWSWIRE) — WillScot Mobile Mini Holdings Corp. (“WillScot Mobile Mini” or the “Company”) (Nasdaq: WSC), a North American leader in modular space and portable storage solutions, today announced the pricing of its previously announced underwritten, secondary offering (the “Offering”) of 14,000,000 shares (the “Shares”) of its common stock, par value $0.0001 per share (the “Common Stock”). The Shares have been offered by the Company’s principal shareholder, Sapphire Holding S.à r.l., an entity controlled by TDR Capital (the “Selling Stockholder”), at a price to the public of $27.95 per share. The Selling Stockholder granted the underwriter a 30-day option to purchase up to an additional 2,100,000 shares. The Company has not offered any shares in the Offering and will not receive any of the proceeds from the Offering. The closing of the Offering is expected to occur on June 25, 2021.

Morgan Stanley has acted as sole underwriter for the Offering.

The Offering is being made pursuant to an effective shelf registration statement, including a base prospectus, that has been filed with the Securities and Exchange Commission (the “SEC”) and became automatically effective on March 1, 2021 and is available on the SEC’s website. A preliminary prospectus supplement and the accompanying base prospectus related to the Offering were filed with the SEC on June 23, 2021 and are available on the SEC’s website. Copies of these documents may be obtained from: Morgan Stanley & Co. LLC, 180 Varick Street, 2nd Floor, New York, NY 10014, Attention: Prospectus Department.

In addition, the Company has entered into a share repurchase agreement with the Selling Stockholder pursuant to which it will repurchase 3,900,000 shares of Common Stock directly from the Selling Stockholder (the “Share Repurchase”). The price per share to be paid by the Company will be equal to the price per Share paid by the underwriters for the Shares in the Offering. The Company expects to fund the Share Repurchase from borrowings under its ABL Credit Facility. The Share Repurchase is expected to be consummated concurrently with the closing of the Offering. Although the Share Repurchase is conditioned upon the closing of the Offering, the closing of the Offering is not conditioned upon the closing of the Share Repurchase.

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company, nor shall there be any sale of securities of the Company in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “estimates,” “expects,” “anticipates,” “believes,” “forecasts,” “plans,” “intends,” “may,” “will,” “should,” “shall,” “outlook” and variations of these words and similar expressions identify forward-looking statements, which are generally not historical in nature. Certain of these forward-looking statements include statements relating to the timing and conduct of the Offering, the size and terms of the Offering and the closing of the Offering. Forward-looking statements are subject to a number of risks, uncertainties, assumptions and other important factors, many of which are outside our control, which could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. These risks include, without limitation, risks and uncertainties related to market conditions, that the size of the Offering could change or the Offering could be terminated, and the satisfaction of customary closing conditions related to the Offering. Any forward-looking statement speaks only at the date which it is made, and WillScot Mobile Mini disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

About WillScot Mobile Mini Holdings Corp.

WillScot Mobile Mini Holdings trades on the Nasdaq stock exchange under the ticker symbol “WSC.” Headquartered in Phoenix, Arizona, the Company is a leading business services provider specializing in innovative flexible workspace and portable storage solutions. WillScot Mobile Mini services diverse end markets across all sectors of the economy from a network of approximately 275 branch locations and additional drop lots throughout the United States, Canada, Mexico, and the United Kingdom.

Contact Information

Investor Inquiries:

Nick Girardi

nick.girardi@willscotmobilemini.com

Media Inquiries:

Scott Junk

scott.junk@willscotmobilemini.com